MaaT Pharma releases positive 18-month data for MaaT013

15 April 2024

French biotech MaaT Pharma (Euronext: MAAT) today announced positive 18-month data for its lead hemato-oncology candidate MaaT013 showing a clear overall survival (OS) advantage in acute graft-versus-host disease (aGvHD) patients treated as part of the company’s Early Access Program (EAP). The firm’s shares edged up 2.3% to $9.70 on the much-awaited news.

The positive efficacy and safety results will be presented at the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on April 17. A pivotal Phase III trial evaluating MaaT013 in patients with aGvHD is currently ongoing to confirm the results from the EAP.

Key findings

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK